Browse > Article
http://dx.doi.org/10.7314/APJCP.2015.16.6.2219

Methylated Alteration of SHP1 Complements Mutation of JAK2 Tyrosine Kinase in Patients with Myeloproliferative Neoplasm  

Yang, Jun-Jun (Department of Laboratory Medicine, The Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University)
Chen, Hui (Department of Laboratory Medicine, The Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University)
Zheng, Xiao-Qun (Department of Laboratory Medicine, The Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University)
Li, Hai-Ying (Laboratory of Internal Medicine, The First Affiliated Hospital of Wenzhou Medical University)
Wu, Jian-Bo (Laboratory of Internal Medicine, The First Affiliated Hospital of Wenzhou Medical University)
Tang, Li-Yuan (Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University)
Gao, Shen-Meng (Laboratory of Internal Medicine, The First Affiliated Hospital of Wenzhou Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.16, no.6, 2015 , pp. 2219-2225 More about this Journal
Abstract
SHP1 negatively regulates the Janus kinase 2/signal transducer and activator of transcription (JAK2/STAT) signaling pathway, which is constitutively activated in myeloproliferative neoplasms (MPNs) and leukemia. Promoter hypermethylation resulting in epigenetic inactivation of SHP1 has been reported in myelomas, leukemias and other cancers. However, whether SHP1 hypermethylation occurs in MPNs, especially in Chinese patients, has remained unclear. Here, we report that aberrant hypermethylation of SHP1 was observed in several leukemic cell lines and bone marrow mononuclear cells from MPN patients. About 51 of 118 (43.2%) MPN patients including 23 of 50 (46%) polycythaemia vera patients, 20 of 50 (40%) essential thrombocythaemia and 8 of 18 (44.4%) idiopathic myelofibrosis showed hypermethylation by methylation-specific polymerase chain reaction. However, SHP1 methylation was not measured in 20 healthy volunteers. Hypermethylation of SHP1 was found in MPN patients with both positive (34/81, 42%) and negative (17/37, 45.9%) JAK2V617F mutation. The levels of SHP1 mRNA were significantly lower in hypermethylated samples than unmethylated samples, suggesting SHP1 may be epigenetically inactivated in MPN patients. Furthermore, treatment with 5-aza-2'-deoxycytidine (AZA) in K562 cells showing hypermethylation of SHP1 led to progressive demethylation of SHP1, with consequently increased reexpression of SHP1. Meanwhile, phosphorylated JAK2 and STAT3 were progressively reduced. Finally, AZA increased the expression of SHP1 in primary MPN cells with hypermethylation of SHP1. Therefore, our data suggest that epigenetic inactivation of SHP1 contributes to the constitutive activation of JAK2/STAT signaling. Restoration of SHP1 expression by AZA may contribute to clinical treatment for MPN patients.
Keywords
SHP1; myeloproliferative neoplasm patients; hypermethylation;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Oka T, Ouchida M, Koyama M, et al (2002). Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Res, 62, 6390-4.
2 Pardanani A, Gotlib JR, Jamieson C, et al (2011). Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol, 29, 789-96.   DOI
3 Pardanani AD, Levine RL, Lasho T, et al (2006). MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood, 108, 3472-6.   DOI
4 Pietra D, Li S, Brisci A, et al (2008). Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood, 111, 1686-9.
5 Shen SH, Bastien L, Posner BI, et al (1991). A protein-tyrosine phosphatase with sequence similarity to the SH2 domain of the protein-tyrosine kinases. Nature, 352, 736-9.   DOI
6 Tefferi A, Vainchenker W (2011). Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol, 29, 573-82.   DOI
7 Tefferi A, Vardiman JW (2008). Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia, 22, 14-22.   DOI
8 Tyner JW, Bumm TG, Deininger J, et al (2010). CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood, 115, 5232-40.   DOI
9 Verstovsek S, Kantarjian HM, Estrov Z, et al (2012a). Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood, 120, 1202-9.   DOI
10 Zhang Y, Zhao D, Zhao H, et al (2012). Hypermethylation of SHP-1 promoter in patient with high-risk myelodysplastic syndrome and it predicts poor prognosis. Med Oncol, 29, 2359-63.   DOI
11 Benekli M, Baer MR, Baumann H, et al (2003). Signal transducer and activator of transcription proteins in leukemias. Blood, 101, 2940-54.   DOI
12 Capello D, Deambrogi C, Rossi D, et al (2008). Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders. Br J Haematol, 141, 504-11.   DOI
13 Chim CS, Fung TK, Cheung WC, et al (2004). SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood, 103, 4630-5.   DOI
14 Gao SM, Chen CQ, Wang LY, et al (2013). Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms. Exp Hematol, 41, 261-70.   DOI
15 Khoury JD, Rassidakis GZ, Medeiros LJ, et al (2004). Methylation of SHP1 gene and loss of SHP1 protein expression are frequent in systemic anaplastic large cell lymphoma. Blood, 104, 1580-1.   DOI
16 Hookham MB, Elliott J, Suessmuth Y, et al (2007). The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood, 109, 4924-9.   DOI
17 James C, Ugo V, Le Couedic JP, et al (2005). A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 434, 1144-8.   DOI
18 Jost E, do ON, Dahl E, et al (2007). Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders. Leukemia, 21, 505-10.   DOI
19 Kumagai C, Kalman B, Middleton FA, et al (2012). Increased promoter methylation of the immune regulatory gene SHP-1 in leukocytes of multiple sclerosis subjects. J Neuroimmunol, 246, 51-7.   DOI
20 Levine RL, Wadleigh M, Cools J, et al (2005). Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 7, 387-97.   DOI
21 Li LC, Dahiya R (2002). MethPrimer: designing primers for methylation PCRs. Bioinformatics, 18, 1427-31.   DOI
22 Nakase K, Cheng J, Zhu Q, et al (2009). Mechanisms of SHP-1 P2 promoter regulation in hematopoietic cells and its silencing in HTLV-1-transformed T cells. J Leukoc Biol, 85, 165-74.
23 Oh ST, Simonds EF, Jones C, et al (2010). Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood, 116, 988-92.   DOI
24 Witkiewicz A, Raghunath P, Wasik A, et al (2007). Loss of SHP-1 tyrosine phosphatase expression correlates with the advanced stages of cutaneous T-cell lymphoma. Hum Pathol, 38, 462-7.   DOI
25 Verstovsek S, Mesa RA, Gotlib J, et al (2012b). A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med, 366, 799-807.   DOI
26 Wang J, Xu Z, Liu L, et al (2013). JAK2V617F allele burden, JAK2 46/1 haplotype and clinical features of Chinese with myeloproliferative neoplasms. Leukemia, 27, 1763-7   DOI
27 Wang Y, Fiskus W, Chong DG, et al (2009). Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood, 114, 5024-33.   DOI
28 Wlodarski P, Zhang Q, Liu X, et al (2007). PU.1 activates transcription of SHP-1 gene in hematopoietic cells. J Biol Chem, 282, 6316-23.
29 Xu SB, Liu XH, Li BH, et al (2009). DNA methylation regulates constitutive expression of Stat6 regulatory genes SOCS-1 and SHP-1 in colon cancer cells. J Cancer Res Clin Oncol, 135, 1791-8.   DOI
30 Xu Z, Gale RP, Zhang Y, et al (2012). Unique features of primary myelofibrosis in Chinese. Blood, 119, 2469-73.   DOI
31 Zhang J, Somani AK, Siminovitch KA (2000). Roles of the SHP-1 tyrosine phosphatase in the negative regulation of cell signalling. Semin Immunol, 12, 361-78.   DOI
32 Zhang Q, Wang HY, Marzec M, et al (2005). STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes. Proc Natl Acad Sci USA, 102, 6948-53.   DOI